We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Procaps Group SA | NASDAQ:PROC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -1.45% | 2.72 | 2.46 | 3.04 | 2.85 | 2.71 | 2.71 | 1,393 | 22:16:11 |
From May 2023 to May 2024
Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time
Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023.
The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results.
To access the call, please use the following information:
Date:
Thursday, November 16, 2023
Time:
10:30 a.m. ET
Webcast:
Click here to access
Toll Free dial-in number:
1-844-204-8586
Toll/International dial-in number:
1-412-317-6346
HD Web Phone:
Click here
Conference ID:
Procaps Group
The conference call will be broadcast live and available for replay here and via Procaps’ investor relations website.
A telephone replay will be available approximately two hours after the call and will run through November 23, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 4127390.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231110834502/en/
Investor Contact: Melissa Angelini ir@procapsgroup.com investor.procapsgroup.com
1 Year Procaps Chart |
1 Month Procaps Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
